Not provided
Not provided
Not provided
Not provided
Study has been prematurely halted because of failure of patient recruitment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Association Nationale pour la promotion de la Dialyse Quotidienne (ANDIQ, France) | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
HDQ 200 is an interventional multicenter study. This is a before-and-after design in which the patient is his own control. The main objective of the study is to determine the percentage of success of a procedure of daily hemodialysis at low dialysate flow. All patients treated with conventional hemodialysis, for at least 3 months and clinically stable, can be included in the study. Their 3 months data prior to inclusion is collected retrospectively. These 3 months of conventional hemodialysis are the reference period. Patients are then treated with daily hemodialysis at low dialysate flow for 3 months. During this 3 months period, the same data as during the period of conventional hemodialysis are collected prospectively.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Daily hemodialysis at low dialysate flow | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Daily hemodialysis at low dialysate flow | Other | Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients for whom the period of daily hemodialysis at low dialysate flow will be a success. | Definition of success: if during the period of daily hemodialysis at low dialysate flow, the patient maintains the absolute value of their pre-dialysis serum creatinine (mid-week dialysis) below the upper limit of the confidence interval established during the 3 months prior to inclusion on 7 values: measurements every 2 weeks for 3 months (retrospective data) and inclusion measurement included (Day 0). Daily hemodialysis at low dialysate flow will be considered as a failure if pre-dialysis serum creatinine values exceed twice successively the upper limit of the confidence interval established for the patient. | Every 2 weeks during 3 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients who stopped the daily hemodialysis at low dialysate flow (patient or investigator's decision). | 3 months. | |
| Number of patients who maintained a satisfactory clinical condition (investigator assessment) during the period of daily hemodialysis at low dialysate flow. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maurice Laville, MD, PHD | Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service de Néphrologie Bâtiment 3C, 3ème étage, Chemin du grand Revoyet 69495 PIERRE-BENITE | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cliniques universitaires St Luc | Brussels | 1200 | Belgium | |||
| ECHO Angers |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 3 months. |
| Evaluation of weight. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks. | During 3 months (retrospectively and prospectively). |
| Evaluation of blood pressure. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks. | During 3 months (retrospectively and prospectively). |
| Evaluation of heart rate. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks. | During 3 months (retrospectively and prospectively). |
| Evaluation of body mass index. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks. | During 3 months (retrospectively and prospectively). |
| Evaluation of metabolic parameters. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks. | During 3 months (retrospectively and prospectively). |
| Evaluation of hematological parameters. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks. | During 3 months (retrospectively and prospectively). |
| Evaluation of inflammation parameters. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): monthly. | During 3 months (retrospectively and prospectively). |
| Evaluation of nutrition parameters. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): monthly. | During 3 months (retrospectively and prospectively). |
| Evaluation of iron parameters. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): monthly. | During 3 months (retrospectively and prospectively). |
| Change in hormones. | Measurement at inclusion represent the retrospective period of 3 months in conventional hemodialysis. Measurement at 3 months represent the prospective period of 3 months in daily hemodialysis at low dialysate flow. | At inclusion and at 3 months. |
| Composite measurement of treatments. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): at each hemodialysis. A listing of all the therapeutics changes made between the two dialysis periods will be provided (e.g. dose of erythropoietin, phosphate binders, antihypertensive drugs, other treatments) | During 3 months (retrospectively and prospectively). |
| Composite measurement of technical dialysis parameters. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. Detail of time frame during 3 months (retrospectively and prospectively): every 2 weeks. A listing of all the technical dialysis changes made between the two dialysis periods will be provided (e.g. urea clearance of the dialysis machine, effective duration of dialysis, ultrafiltration time rate and per dialysis, type of access, blood flow, dialysate flow rate, dialysate composition and anticoagulation method). | During 3 months (retrospectively and prospectively). |
| List of symptoms and incidents between two hemodialysis, evaluation of hemodialysis tolerance, clinical assessment of the vascular access and possible local complications. | The retrospective study period is 3 months of conventional hemodialysis. The prospective study period is 3 months of daily hemodialysis at low dialysate flow. | At each hemodialysis during 3 months (retrospectively and prospectively). |
| Change in quality of life. | Measurement at inclusion represent the retrospective period of 3 months in conventional hemodialysis. Measurement at 3 months represent the prospective period of 3 months in daily hemodialysis at low dialysate flow. | At inclusion and at 3 months. |
| Change in pain. | Measurement at inclusion represent the retrospective period of 3 months in conventional hemodialysis. Measurement at 3 months represent the prospective period of 3 months in daily hemodialysis at low dialysate flow. | At inclusion and at 3 months. |
| Angers |
| 49055 |
| France |
| CTMR Saint Augustin | Bordeaux | 33000 | France |
| CHPC | Cherbourg | 50102 | France |
| CHU Grenoble | Grenoble | 38043 | France |
| ANIDER | Le Petit-Quevilly | 76143 | France |
| AURAL | Lyon | 69008 | France |
| Hospices Civils de Lyon - Hôpital Edouard Herriot | Lyon | 69437 | France |
| AGDUC Meylan | Meylan | 38240 | France |
| AURA - Paris | Paris | 75015 | France |
| Hospices Civils de Lyon - Centre Hospitalier Lyon Sud | Pierre-Bénite | 69495 | France |
| ECHO Nantes | Rezé | 44402 | France |
| Centre Hospitalier de Vichy | Vichy | 03201 | France |
| ID | Term |
|---|---|
| D007676 | Kidney Failure, Chronic |
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided